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Abnormal platelet cytoskeletal assembly in hemodialyzed pa- Extensive literature exists describing the bleeding dis-
tients results in deficient tyrosine phosphorylation signaling. order suffered by uremic patients. This tendency to bleed
Background. Uremic patients have a bleeding tendency as- observed in uremia is multifactorial: It has been associ-sociated with a platelet dysfunction. We evaluated the impact
ated with a platelet dysfunction, as there are no majorof a repeated hemodialysis procedure on primary hemostasis
alterations in the coagulation system, but its origin re-by analyzing different aspects of platelet activation in uremic
patients. mains obscure [1–6]. Platelets from uremic patients pres-
Methods. Studies were performed in (1) eight patients with ent an impaired adhesion [7], which is manifested by
end-stage renal disease before the hemodialysis program was defective spreading on subendothelial surfaces in experi-initiated and after initiating hemodialysis treatment, and in (2)
ments performed with flowing blood [8]. However, ure-eight patients on maintenance hemodialysis who were trans-
mic patients have normal or even increased plasma levelsferred to continuous ambulatory peritoneal dialysis. Studies in-
cluded routine platelet aggregations and evaluation of platelet– of von Willebrand factor (vWF) [9], the adhesive protein
subendothelium interactions under flow conditions. Contractile with a major role in platelet adhesion [10]. The presence
proteins and tyrosine phosphorylation associated with the cy-
and binding functions of platelet membrane receptorstoskeleton were analyzed, before and after thrombin activation
(GPIb and GPIIb-IIIa) in these patients have been foundof platelets, by electrophoresis after Triton X-100 extraction.
Results. No changes in the clinical parameters analyzed were to be generally preserved [11–13], although some minor
observed among the different study groups. Aggregation and abnormalities have been reported in patients with end-
platelet adhesion only improved when patients were shifted stage renal disease [14, 15].
from hemodialysis to continuous ambulatory peritoneal dial-
Recent studies have suggested a cytoskeletal abnor-ysis (P , 0.05 for both percentage of surface covered by plate-
mality of uremic platelets to fully spread under staticlets and aggregate formation). The association of cytoskeletal
proteins in platelets from patients under hemodialysis treat- conditions [16]. This limitation of adhesive capabilities
ment was statistically decreased with respect to the correspond- was found to be associated with an impaired organization
ing values in platelets from patients not subjected to dialysis of contractile proteins into the cytoskeleton of suspen-
(P , 0.01 for actin). However, after two months on peritoneal
sion-activated platelets. The removal of uremic toxinsdialysis, these values increased to almost control values (P ,
by dialysis only partially corrects the abnormal platelet0.001 for actin, vs. hemodialysis). Similarly, translocation of
tyrosine-phosphorylated proteins to the cytoskeletal fraction function observed in uremic patients [3, 6, 17]. However,
was impaired in platelets from hemodialyzed patients, and it hemodialysis (HD) procedures are known to produce
recovered partially after the patients transferred to continuous profound activation, which adversely affects platelet
ambulatory peritoneal dialysis.
function [18–23]. Repeated activation of platelets duringConclusions. Our present data support the concept that re-
maintenance HD may result in consecutive cycles ofpeated platelet stress during hemodialysis has a deleterious
effect on the organization of platelet cytoskeleton, which seems polymerization and depolymerization of the cytoskeletal
to impair the translocation of signal transduction proteins proteins, leading to the development of a certain degree
within platelets compromising the platelet function in uremia. of platelet refractoriness. On the other hand, peritoneal
dialysis is more effective in improving platelet function
and bleeding times [24, 25].Key words: hemodialysis, peritoneal dialysis, cytoskeleton, phospho-
tyrosine proteins, signal transduction, uremia. Two main components of the platelet cytoskeleton are
currently considered: the cytoplasmic portion composedReceived for publication February 16, 1999
of actin filaments (F-actin) and the membrane cytoskele-and in revised form October 8, 1999
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terized proteins. In resting platelets, the membrane cy- including the lack of vascular access for HD (5), ischemic
heart disease (2), and personal decision of the patienttoskeleton acts to stabilize the plasma membrane and
regulate the platelet shape. While some signaling mole- (1). Patients performed HD for four hours three time per
week, and hollow fiber dialyzers with cellulose acetatecules in resting platelets have been found to be associated
with the membrane skeleton, tightly related to the extra- membranes (CA 140; Baxter, Deerfield, IL, USA) were
used. None of the patients complained of severe bleedingcellular receptors, after activation of platelets they be-
come associated with the cytoplasmic cytoskeleton. An or were hypertensive at the time that they were enrolled
in the study. The KT/V in all hemodialyzed patients wasassociation between membrane and cytoplasmic cyto-
skeletons results in platelet motion and internal contrac- higher than 1.1. No patient had received blood related
products for two months, and none had taken aspirin ortion necessary for release. Recent investigations have
demonstrated that the cytoskeleton plays a role in localiz- other drugs that affect platelet function for at least two
weeks prior to the study.ing signaling molecules, facilitating their function [26].
Therefore, platelet cytoskeleton may act as a connection
Experimental designbetween the extracellular receptors and the cytoplasmic
signaling proteins. Derangement of the cytoskeletal or- Studies were carried out on (1) eight patients with
ESRD before the HD program was initiated (pre-HD)ganization thus may lead to impaired signal transduction
processes. and after undergoing HD (post-HD), and (2) eight pa-
tients while on maintenance HD and at least two monthsWe have evaluated the impact of standard HD on the
platelet dysfunction observed in uremia. Studies were after starting CAPD treatment. Blood samples from
healthy volunteers were also obtained for control experi-developed for two groups of uremic patients: (1) eight
patients with end-stage renal disease (ESRD) before ments. Studies included the evaluation of certain clinical
parameters, including bleeding times and platelet aggre-initiating renal replacement therapy and two months
after starting HD treatment, and (2) eight uremic pa- gation using turbidimetric techniques, and the evaluation
of platelet–subendothelium interactions under flow con-tients on maintenance HD who were transferred to peri-
toneal dialysis for clinical reasons. Studies included ditions, using an annular perfusion chamber. The associ-
ation of contractile and phosphotyrosine proteins withbleeding times, platelet aggregations, and evaluation of
platelet–subendothelium interactions under flow condi- the platelet cytoskeleton after thrombin stimulation was
also investigated by sodium dodecyl sulfate-polyacryl-tions. Changes induced in the association of contractile
and tyrosine-phosphorylated proteins with the cytoskele- amide gel electrophoresis (SDS-PAGE) in both groups
of patients under the different treatments.ton, before and after thrombin stimulation, were evalu-
ated by electrophoretic techniques. In each set of experiments, studies were performed
using blood from two uremic patients and from a control
donor. This design was applied in studies performed while
METHODS
patients were in pre-treatment and post-treatment, con-
Patients sidering that blood samples were always obtained from
different donors. Therefore, the number for each groupOur study, approved by the Human Experimental
Committee of the Hospital Clinic, was carried out ac- of patients was 8, and the number for the control group
was 16.cording to the principles of the Declaration of Helsinki.
Informed consent was obtained from all the participants.
Blood samplingEight patients with end-stage renal disease (clearance
creatinine , 10 mL/min) were evaluated before starting Blood samples were obtained from uremic patients
(1) before initiating HD and after at least two monthsHD and after two months on maintenance HD. There
were five men and three women from the age of 38 to of starting HD and (2) while under HD and after two
months of being transferred to CAPD. In those patients62 years. The causes of renal failure were nephrosclerosis
(3), chronic glomerulonephritis (3), diabetic nephropa- under HD treatment, blood samples were always ob-
tained just before the HD session. Aliquots of citratedthy (1), and unknown (1). Eight uremic patients on main-
tenance HD (6 women and 2 men, age range of 42 to blood samples were reserved for perfusion studies. Plate-
let-rich plasma (PRP) was obtained by centrifugation of75 years, time on HD from 6 to 171 months) were in-
cluded in this study. The causes of renal failure were citrate-anticoagulated blood for 20 minutes at 100 3 g.
Aliquots of PRP were used in aggregation studies.polycystic kidney disease (2), diabetic nephropathy (2),
nephroangiosclerosis (1), chronic interstitial nephropa- Platelets were also isolated from PRP and were
washed twice with equal volumes of CCD (93 mmol/Lthy (1), hemolytic uremic syndrome (1), and unknown
(1). Patients included in the study were chosen on the sodium citrate, 7 mmol/L citric acid, and 140 mmol/L
dextrose), pH 6.5, containing 5 mmol/L adenosine andbasis that they were moved from HD to continuous am-
bulatory peritoneal dialysis (CAPD) for various reasons, 3 mmol/L theophylline [27]. The final pellet was resus-
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pended in Hanks’ balanced salt solution (HBSS) and remaining undisturbed at 378C and one being subjected
to stimulation with 0.1 U/mL thrombin. Samples wereincubated for 20 minutes at 378C. Aliquots of washed
uremic platelet suspensions were used to electrophoreti- mixed by gentle inversion every 30 seconds. After 90
seconds, all of the samples were treated with an equalcally analyze any changes in the association of contractile
proteins to the cytoskeleton before and after activation volume of ice-cold lysis buffer (final pH 7.4) containing
2% Triton X-100, 100 mmol/L Tris-HCl, 10 mmol/L eth-with 0.1 U/mL of thrombin.
ylene glycol bis(b-aminoethylether)-N,N,N9,N9-tetraace-
Aggregation studies tic acid (EGTA), 4 mmol/L ethylenediaminetetraacetic
acid (EDTA), 2 mmol/L phenylmethylsulfonyl fluoridePlatelet aggregation studies were carried out in a Hi-
tachi-Aggrecorder aggregometer. Samples of PRP from (PMSF), 1 mmol/L benzamidine, 2 mg/mL leupeptin, 2
mg/mL pepstatin, and 2 mmol/L sodium orthovanadate.the uremic patients included in the study were placed in
6 mm wide siliconized cuvettes. Platelet counts were The low-speed Triton-insoluble residues, corresponding
to the polymerized cytoskeletal fraction, were isolatednormalized to the same value (2 3 105 platelets/mL).
The minimum and maximum amplitudes of the recorder by sedimentation at 12,000 3 g for five minutes at 48C
in a microfuge. After collection of the supernatants, resi-were adjusted with PRP (0% transmission) and platelet
poor plasma (PPP) (100% transmission), respectively. dues were washed twice with washing buffer, without
Triton X-100, at 48C, solubilized with a SDS-containingArachidonic acid (1.2 mmol/L), adenosine diphosphate
(ADP; 4 mmol/L), collagen (2.5 mg/mL), epinephrine buffer, and heated at 1008C for five minutes. Platelet
membrane cytoskeletons were sedimented by centrifuga-(10 mmol/L), and ristocetin (1 mg/mL) were used as
inductors, under stirring. Results were expressed as per- tion of the supernatants, recovered at low speed, at
100,000 3 g for three hours. The corresponding pelletscentages of maximum aggregation obtained after five
minutes of stimulation [28, 29]. (high-speed residues) were solubilized as mentioned be-
fore. Samples were frozen at 2408C until electrophoreti-
Perfusion studies and morphometric evaluation cal evaluation was performed.
Perfusion experiments were performed in annular
Analysis of cytoskeletal proteinschambers, as previously described [30, 31]. De-endothe-
lialized rabbit aorta segments were exposed to citrated Triton-insoluble fractions from an equal number of
thrombin nonactivated and activated platelets were ob-whole blood at a shear rate of 800 s21 at 378C. After 10
minutes of perfusion, segments were fixed, dehydrated tained from control donors and from the uremic patients
enrolled in the study. Cytoskeletal proteins present inwith alcohols, embedded in JB-4, thin sectioned for light
microscopy, and stained with toluidine blue. both the low- and high-speed fractions were separated
by 7 to 12% SDS-PAGE [35]. To evaluate the contractilePlatelets interacting with subendothelium were evalu-
ated according to the morphometric criteria described by proteins associated with the cytoskeleton, gels were
stained with Coomassie brilliant blue R250 and densito-Baumgartner and Muggli [30]. A semiautomated method
was used to divide platelets into different classes of inter- metrically quantitated as previously described [16]. Basi-
cally, stained protein bands were densitometrically ana-action [32]. Platelets or groups of platelets were classified
as follows: contact (C), platelets that were attached but lyzed using digital-video technology provided by a
computerized image analyzer running specific softwarenot spread on the subendothelium; adhesion (A), plate-
lets that were spread on subendothelium or form layers (SigmaGel, Jandel GmbH, Erkrath, Germany). After
selection of the bands on the monitor screen, the soft-of less than 5 mm in height; and thrombi (T), platelet
aggregates of 5 mm or more in height. All of these basic ware automatically analyzed the color density of each
protein band and integrated areas beneath densitometricparameters were expressed as a percentage of the total
length of the vessel screened. The total covered surface peaks. Values of protein peak areas in the lanes con-
taining Triton-insoluble residues from nonactivated(CS) was obtained by adding the previous basic parame-
ters (C 1 A 1 T). platelets were considered as 100%. The association of
certain protein with the thrombin-activated cytoskeleton
Obtaining cytoskeletal proteins was expressed as the percentage of increase over the
amount of the same protein found in the respective lanePlatelet cytoskeletons were obtained according to the
procedure described by Jennings et al [33] with minor corresponding to nonactivated platelets.
modifications [34]. Samples of resuspended platelets were
Analysis of tyrosine-phosphorylated proteinsadjusted to 1.2 3 106 platelets/mL. Before activation of
platelets, aliquots of platelet suspensions were treated Phosphotyrosine proteins associated with both the
low- and high-speed cytoskeletal fractions were analyzedto quantitate the protein content, which was always com-
parable among the samples obtained (around 2 mg/mL). on 8% SDS-polyacrylamide gels. Proteins present in the
gels were transferred to nitrocellulose membranes (Bio-Platelet suspensions were divided into two aliquots, one
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Table 1. Changes in blood cell counts and laboratory parameters
Pre-HD Post-HD HD CAPD
Hemoglobin g/L 84.265.6 87.364.1 88.7611.5 91.1613.6
Hematocrit % 25.561.6 26.860.9 28.665.3 29.465.4
Platelet count 3 103/mL 193.8620 201624 309.7654 323.1669
BUN mg/dL 108.5610 93.569.5 78.1614.6 77.2614.6
Creatinine mg/dL 9.061 8.760.9 10.662.2 11.562.1
Hemoglobin, hematocrit, platelet count, BUN and creatinine values were measured in (1) patients with end-stage renal disease before (pre-HD) and after two
months of initiating hemodialysis (post-HD), and in (2) patients undergoing hemodialysis (HD) and after transferring to continuous ambulatory peritoneal dialysis
(CAPD). No significant changes were observed in the parameters analyzed. Data are expressed as mean 6 SEM. N 5 8 for both groups.
Rad, Hercules, CA, USA). After blocking nonspecific sponse to the agonists used, when compared with control
values (P , 0.05; Table 2).binding, Western blots were probed with a horseradish
After five minutes of PRP stimulation with arachi-peroxidase-antiphosphotyrosine recombinant antibody
donic acid (1.2 mmol/L), collagen (2.5 mg/mL), ADP(Transduction Laboratories, Lexington, KY, USA). The
(4 mmol/L), and ristocetin (1 mg/mL), percentages ofexcess of antibody was removed by extensive washing,
maximal aggregation were 68.5 6 6.5%, 76 6 3.5%, 69.1 6and blots were developed by enhanced chemiluminis-
5.3%, and 72.9 6 4.0%, respectively (mean 6 SEM, N 5cence (ECL) method (Amersham Pharmacia Biotek, Es-
8) in patients with pre-HD ESRD. In the same group ofsex, UK).
patients, aggregation patterns did not significantly differ
Statistics after two months of starting HD. Aggregation values
were 61.8 6 3.0%, 78.8 6 3.6%, 64.9 6 4.8%, and 66.4 6Data are expressed as mean 6 SEM. Student’s t-test
2.5%, respectively.for paired data was used for statistical comparisons be-
Aggregation responses of platelets from the secondtween data obtained pretreatment and posttreatment in
group of uremic patients, while on HD, to arachidoniceach group. Student’s t-test was used to compare data
acid, collagen, ADP, and ristocetin at the concentrationsfrom patients versus controls. A P level , 0.05 was con-
indicated before were 55.8 6 6.8%, 60.2 6 8.3%, 56.2 6sidered statistically significant.
7.8%, and 65.7 6 8.9%, respectively (mean 6 SEM, N 5
8). Under the same experimental conditions, all of the
RESULTS aggregation patterns statistically improved (P , 0.05)
when patients were moved to CAPD, changing to 78.9 6Clinical parameters
6.9%, 81.2 6 7.5%, 79.1 6 7.6%, and 89.2 6 7.1%,Table 1 shows changes in blood cell counts and labora-
respectively (Table 2).tory parameters. Hematocrit and hemoglobin levels of
the uremic patients enrolled in the study were measured Perfusion studies
in pre-HD, post-HD, HD, and CAPD situations of the
Blood samples were recirculated for 10 minutes
study. These values showed practically the same levels through the annular chamber at 800 s21 of shear rate.
during the different treatments in both groups of pa- Values of surface covered by platelets, expressed as per-
tients. Platelet counts and coagulation tests (prothrom- centages (%SC) obtained with control blood samples
bin time, partial thromboplastin time, and fibrinogen were 34.5 6 3.4% with an aggregate formation of 20.4 6
levels) were within the normal range in both groups 2.5% (mean 6 SEM, N 5 16).
under the different periods of the study. Plasma levels Studies of uremic patients before and after two months
of nitrogen-retention products and creatinine levels did of initiating HD treatment. The surface covered by plate-
not change after initiating HD (post-HD) or while on lets obtained after perfusing denuded vascular segments
HD, and they were similar or increased slightly after with blood samples from patients with ESRD was 24.1 6
starting CAPD. No significant differences were observed 1.9% (mean 6 SEM, N 5 8), with an aggregate formation
when comparing bleeding times among the different of 15.7 6 0.5%. After two months of initiating HD treat-
treatments in both groups of patients. ment, perfusion experiments were carried out with blood
samples from the same patients. Results of %SC and
Aggregation studies percentage aggregate formation were slightly inferior
Aggregation results for control platelets reached val- (21.7 6 2% and 13.4 6 2.3%, respectively), but did not
ues of approximately 100% of aggregation five minutes statistically vary from pre-HD values. Values of surface
after the addition of the agonists at the concentrations coverage observed in both situations were statistically
employed. Platelet suspensions from all the patients in- reduced with respect to those observed in control experi-
ments (P , 0.05; Fig. 1A).cluded in the study showed a reduced aggregating re-
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Table 2. Bleeding time and platelet aggregation studies
Pre-HD Post-HD HD CAPD Normal range
Bleeding time min 8.262.3 7.062.8 9.363.2 8.363.8 3–8
AA 1.2 mmol/L 68.566.5 61.863.0 55.866.8 78.966.9a 75–100
Col 2.5 lg/mL 76.063.5 78.863.6 60.268.3 81.267.5a 68–100
ADP 4 lmol/L 69.165.3 64.964.8 56.267.8 79.167.6a 75–100
Risto 1 mg/mL 72.964.0 66.462.5 65.768.9 89.267.1a 70–100
Bleeding time (min) and aggregation results (% of maximal aggregation) after 5 minutes of stimulation of platelet-rich plasma (PRP) obtained from two groups
of uremic patients: (1) eight patients with end-stage renal disease before (pre-HD) and after two months of initiating hemodialysis (post-HD), and (2) eight patients
undergoing hemodialysis (HD) and after transferring to continuous ambulatory peritoneal dialysis (CAPD). Aggregation studies were performed with the agonists
arachidonic acid (AA), collagen (Col), adenosine diphosphate (ADP), and ristocetin (Risto). No differences were observed among pre-HD and post-HD results.
Transfer to CAPD treatment resulted in a statistically significant increase in the aggregation profiles (aP , 0.05). Data are expressed as mean 6 SEM, N 5 8 for
both groups.
Studies of HD patients who were transferred to CAPD.
The %SC using blood from the uremic patients while
on HD was 18.6 6 4.5% (mean 6 SEM, N 5 8), which
was significantly below that obtained in control experi-
ments (P , 0.05). After CAPD began, platelets from
the same uremic patients displayed a higher surface cov-
erage, increasing statistically to 24.6 6 3.3% (P , 0.05).
This increase in the surface coverage paralleled a statisti-
cally significant improvement of the aggregate forma-
tion: from 12.3 6 4.4% when patients were on HD, to
17.6 6 5% after two months of CAPD treatment (P ,
0.05; Fig. 1B).
Changes in the distribution of platelet
cytoskeletal proteins
Profiles corresponding to the low-speed Triton X-100–
insoluble residues of resting platelets and platelets acti-
vated with thrombin from control donors and from both
groups of uremic patients included in the study who
underwent the different treatments (Fig. 2) were ana-
lyzed densitometrically. The degree of association of the
different proteins with the cytoskeleton was expressed
as the percentage of incorporation of each protein in
thrombin stimulated versus resting platelet samples.
Profiles corresponding to resting platelets from the
control donors and from all of the uremic patients in-
cluded in the study showed no significant qualitative
differences for the presence of the major cytoskeletal
proteins recovered in the low-speed cytoskeletal fraction
(Fig. 2, lanes 1, 3, and 5). However, proteins in profiles
from uremic patients on HD treatment densitometrically
appeared to be decreased (Fig. 2, lane 3).
Fig. 1. Platelet deposition after 10 minutes of perfusion of denuded
Thrombin activation of control platelets resulted inrabbit aorta. Perfusates consisted of blood samples from (A) eight
patients with end-stage renal disease before (pre-HD) and after (post- an augmented incorporation of contractile proteins (Fig.
HD) two months of initiating HD treatment, and (B) eight patients 2, lane 2). Incorporations of ABP, myosin, a-actinin,while on HD and after being transferred to CAPD. Bar diagrams
and actin to the low-speed cytoskeletal fraction afterrepresent morphometric parameters obtained in the different perfusion
experiments. Bars represent the percentage of the vessel surface covered thrombin stimulation were 140 6 5%, 50 6 11.4%, 61.4 6
with platelets. The open portion of the bar corresponds to the surface 7.9%, and 120 6 4.6%, respectively (Fig. 3).covered by adhesive platelets (adhesion), and the dashed inserts indicate
Studies of uremic patients before and after two monthsthe surface covered with groups of platelets forming aggregates of more
than 5 mm in height (thrombi). The results are expressed as percentages of initiating HD treatment. Proteins recovered at the
of the total surface of the vessel screened. *P , 0.05 vs. control values low-speed cytoskeletal fraction corresponding to throm-and aP , 0.05 CAPD vs. HD. N 5 16 for control experiments and
N 5 8 for each group of uremic patients. bin-activated platelets from eight uremic patients with
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Fig. 2. Coomassie brilliant blue-stained SDS
polyacrylamide gels showing protein profiles
corresponding to the low-speed cytoskeletal
fraction. Platelet suspensions were obtained
from control donors (lanes 1 and 2); uremic
patients undergoing HD treatment (lanes 3
and 4) and after being moved to CAPD treat-
ment (lanes 5 and 6). Cytoskeletal assembly
was evaluated before (lanes 1, 3, and 5) and
after activation with 0.1 U/mL of thrombin
for 90 seconds (lanes 2, 4, and 6). Arrowheads
indicate defective association of contractile
proteins after thrombin activation of platelets
from patients under HD. Profiles shown corre-
spond to one experiment and are representa-
tive of the eight different experiments per-
formed.
ESRD, pre-HD, were also analyzed. After activation corporation of 110 6 6% vs. 42 6 2% for ABP (P ,
0.01), 45.8 6 8.0% vs. 35.0 6 6.0% for myosin, 53.6 6of platelets with 0.1 U/mL of thrombin, there was an
incorporation of contractile proteins of 87.5 6 4.3%, 3.2% vs. 18.0 6 4% for a-actinin (P , 0.01), and 96 6
1.2% vs. 36 6 3.2% for actin (P , 0.01)]. The association45.0 6 5.3%, 45.7 6 7%, and 74.8 6 4.2% for ABP,
myosin, a-actinin, and actin, respectively. of myosin after thrombin activation was not significantly
different in the two situations.In studies performed post-HD, blood samples from the
same patients were collected, and the same experimental Figure 4 shows SDS-PAGE profiles corresponding to
the high-speed cytoskeletal fraction from resting andconditions were applied. When platelets were activated
with thrombin, incorporation of contractile proteins to thrombin-activated platelets. Profiles correspond to an
equal number of platelets from the control donors andthe low-speed cytoskeletal fraction was significantly de-
creased (P , 0.01 vs. pre-HD for all the proteins studied). the uremic patients included in the study. No significant
differences were observed among the profiles from rest-Results in terms of protein incorporation were 60.6 6
6.3%, 35.9 6 5.6%, 25.6 6 5.0%, and 34.4 6 8% for ing platelets obtained from control donors and uremic
patients after initiating CAPD (Fig. 4, lanes 1 and 5).ABP, myosin, a-actinin and actin, respectively (Fig. 3A).
Studies of patients on HD who transferred to CAPD However, lane 3 in Figure 4 shows that the amount
of proteins associated with the high-speed cytoskeletaltreatment. Amounts of proteins found in cytoskeletons
from resting platelets obtained from the patients under- fraction in platelets from patients undergoing HD was
increased, correlating to a decrease in the density ofgoing CAPD were slightly greater to those observed in
platelets from the same patients while they were on HD. those proteins associated with the low-speed cytoskeletal
fraction (Fig. 2, lane 3).After thrombin stimulation, an incorporation of contrac-
tile proteins to the cytoskeleton of platelets from the After thrombin activation, the contractile proteins as-
sociated with this fraction decreased in control plateletssame patients was observed during both the HD and
CAPD treatments, although the rate of incorporation (46 6 2.8% decrease of actin). This was actually expected
since polymerized contractile proteins were recoveredwas much higher in platelets obtained while patients
were on CAPD (Fig. 2). in the low-speed fraction (Fig. 4, lane 2 vs. lane 1), due
to the cytoskeleton assembly. Nearly similar results wereDensitometric evaluation (Fig. 3B) of protein bands
corresponding to Triton-insoluble residues of thrombin- observed in profiles corresponding to the platelets from
patients who were pre-HD and those after CAPD treat-activated platelets from patients under CAPD showed
a statistically significant increase in the association of ment (percentage of decrease of 62 6 0.9% and 50 6
1.8%, respectively; Fig. 4, lane 6 vs. lane 5).ABP, a-actinin, and actin versus those obtained when
patients were undergoing HD treatment [%protein in- However, when analyzing the protein profiles corre-
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after being transferred to CAPD. Studies were per-
formed in order to evaluate changes in the association
of these proteins with both the low- and high-speed cy-
toskeletal fractions after thrombin activation in the situa-
tions analyzed.
Figure 5 shows profiles corresponding to the low-speed
cytoskeletal fraction from control and uremic platelets
from HD patients and those who were transferred to
CAPD. Under nonactivating conditions, almost unde-
tectable phosphorylation was present. After thrombin
activation for 90 seconds, some of the proteins associated
with the low-speed pellet from control platelets (proteins
p120, p85, p78, p75, pp62, pp60, and p54) were phosphor-
ylated.
When analyzing the profiles corresponding to platelets
from uremic patients under HD, we did not observe de-
tectable phosphorylation after thrombin activation. Only
in two of the patients studied could traces of tyrosine-
phosphorylated proteins be detected. However, phos-
phorylation patterns recovered to almost control levels
when patients were transferred to CAPD.
Tyrosine phosphorylation associated with the high-
speed fraction obtained from control platelets was low
under both basal and stimulating conditions (Fig. 6). Only
p100 and pp60 appeared slightly phosphorylated. How-
ever, phosphorylation levels in profiles from nonactivated
platelets from uremic patients under HD were signifi-
cantly higher than in controls. Proteins p100, pp62, and
pp60 were initially phosphorylated and remained at simi-
lar or even higher levels after thrombin activation. Trans-
fer to CAPD induced a normalization of the phosphory-Fig. 3. Percent increase in the incorporation of cytoskeletal proteins
after activation with 0.1 U/mL of thrombin. Values express percentages lation patterns associated with this cytoskeletal fraction.
of increase (mean 6 SEM) over the amount of the same protein in
cytoskeletons of nonactivated platelets. Experiments were performed
with platelet suspensions from the same patient (A) before (pre-HD) DISCUSSION
and after (post-HD) two months of initiating HD treatment, and (B)
while on HD and after transfer to CAPD. Control results are also Data from our present study suggest that repeated
represented. *P , 0.01; **P , 0.001. N 5 16 for the control group and platelet stress during current HD procedures has a dele-
N 5 8 for each group of uremic patients. Symbols are: (h) control;
terious effect on platelet function. This negative effect( ) HD; ( ) CAPD.
would be characterized by an impairment of platelet
cytoskeletal assembly and in an abnormal translocation
of the signaling molecules studied in response to activa-
sponding to platelets obtained from patients in both tion. Moreover, CAPD would be less aggressive on these
groups under HD treatment, either post-HD or HD, we functional and biochemical mechanisms.
did not observe significant differences among the profiles Patients with chronic renal failure have a hemorrhagic
from nonactivated and thrombin-activated platelets (Fig. tendency [3, 4]. This bleeding disorder seems to have a
4, lanes 3 and 4, respectively). After thrombin activation, multifactorial origin and has been associated with a plate-
actin decreased in 16 6 2% and 14 6 3% in profiles let dysfunction. Our group reported that uremic patients
corresponding to platelets from patients undergoing with a clinical history of hemorrhagic disorders showed
post-HD and HD treatments, respectively. a defective platelet adhesion with vessel subendothelium
in experiments under flow conditions [7]. Further studies
Distribution of phosphotyrosine proteins have confirmed the functional impairment of uremic
within platelets platelets, demonstrated by a limitation of the platelet-
Thrombin-induced changes in the tyrosine-phosphor- spreading capabilities [8]. Other authors have also found
ylation patterns of proteins were analyzed in platelets a defect in the adhesive and cohesive platelet functions
in uremic patients, attributed to factors in plasma [36].from control donors and uremic patients under HD and
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Fig. 4. Coomassie brilliant blue-stained SDS
polyacrylamide gels showing protein profiles
corresponding to the high-speed cytoskeletal
fraction. Platelet suspensions were obtained
from control donors (lanes 1 and 2); uremic
patients under HD treatment (lanes 3 and 4)
and after transfer to CAPD treatment (lanes
5 and 6). Cytoskeletal assembly was evaluated
before (lanes 1, 3, and 5) and after activation
with 0.1 U/mL of thrombin for 90 seconds
(lanes 2, 4, and 6). Profiles shown correspond
to one experiment and are representative of
the eight different experiments performed.
The present study was designed to evaluate how re- and artificial surfaces [16]. Moreover, the biochemical
peated stress by HD could have a deleterious effect on evaluation by electrophoresis of cytoskeletal assembly
primary hemostasis. Results from our studies in the after thrombin stimulation of uremic platelets under HD
group of patients with ESRD who had just started HD treatment showed a defective incorporation of the con-
treatment indicate that this procedure does not imply tractile proteins when compared with that observed in
an improvement of platelet function. Moreover, cyto- control platelets [16, 40]. Our present results confirm
skeletal assembly in response to thrombin seems to be those observations.
compromised as early as two months after starting HD Platelet cytoskeleton also plays a role in localizing
treatment. Further evidence was obtained from studies signaling molecules. In platelets from healthy individu-
on patients who were switched from HD to CAPD. Our als, some of the proteins susceptible to be phosphory-
present observations in this group of patients reinforce lated at tyrosine residues are known to be localized at
the findings obtained by other authors in terms of aggre- a submembrane level in resting conditions [26]. After
gating platelet responses [6, 17, 37], indicating a recovery thrombin activation and as we have observed in control
of the cohesive functions of uremic platelets in patients platelets, they appeared phosphorylated and associated
undergoing CAPD. Furthermore, the use of the Baum- with the cytoplasmic cytoskeleton (recovered at the low-
gartner perfusion method in our present study has dem-
speed cytoskeletal fraction). In platelets from uremic
onstrated that not only were the aggregating responses of
patients under HD treatment, in which the cytoskeletaluremic platelets better preserved, but that the adhesive
assembly was defective, a certain degree of tyrosinefunctions improved in the same uremic patients while
phosphorylation was detected but not properly associ-on CAPD. Interestingly, those improvements were asso-
ated with the polymerized cytoskeletal matrix (low-ciated with an amelioration of the cytoskeletal assembly
speed fraction). In our study, the shift from HD to CAPDin response to thrombin, suggesting that this might be the
treatment resulted in a partial recovery of the cytoskele-underlying mechanism of the platelet function recovery.
tal response of uremic platelets. Interestingly, signalingThe molecular assembly of actin into a filamentous
through tyrosine phosphorylation in platelets from pa-network and the organization of other structural proteins
tients under CAPD treatment showed similar patternsof the cytoskeleton are of critical importance for platelet
to those observed in control platelets. In this group ofshape change and internal contraction [38, 39]. During
patients, the nitrogen retention products and creatininethese events, the contractile proteins that constitute both
levels did not change or even increase slightly under themembrane and cytoplasmic cytoskeletons rearrange
CAPD therapy. Therefore, this improvement seems tothemselves through polymerization and depolymeriza-
be unrelated to a correction of the uremic status of thetion processes. Previous studies performed in uremic
patients. The better preservation of platelet cytoskeletalpatients on maintenance HD who had a history of bleed-
ing showed a platelet-spreading defect on vascular [7, 8] functions may be in agreement with the improved he-
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Fig. 6. Tyrosine-phosphorylated proteins associated with the high-speed
cytoskeletal fraction from platelets before (lanes 1, 3, and 5) and afterFig. 5. Tyrosine-phosphorylated proteins associated with the low-speed
activation with 0.1 U/mL of thrombin (lanes 2, 4, and 6). Platelets werecytoskeletal fraction from platelets before (lanes 1, 3, and 5) and after
obtained from control donors (lanes 1 and 2); uremic patients underactivation with 0.1 U/mL of thrombin (lanes 2, 4, and 6). Platelets were
HD treatment (lanes 3 and 4) and after transfer to CAPD treatmentobtained from control donors (lanes 1 and 2); uremic patients under
(lanes 5 and 6). After electrophoresis of the high-speed Triton-insolubleHD treatment (lanes 3 and 4) and after transfer to CAPD treatment
cytoskeletal fractions through SDS polyacrylamide gels, proteins were(lanes 5 and 6). After electrophoresis of the low-speed Triton-insoluble
transferred to nitrocellulose membranes. Blots were incubated with acytoskeletal fractions through SDS polyacrylamide gels, proteins were
peroxidase-conjugated antibody to phosphotyrosine residues and de-transferred to nitrocellulose membranes. Blots were incubated with a
tected by ECL. Profiles shown correspond to one experiment and areperoxidase-conjugated antibody to phosphotyrosine residues and de-
representative of the eight different experiments performed.tected by ECL. The profiles shown correspond to one experiment and
are representative of the eight different experiments performed.
switched to CAPD. The recovery of platelet function
was not related to an increase in platelet or erythrocytemostasis observed by previous authors in patients with
counts, nor to an improvement of the uremic milieu. InCAPD treatment [24, 25, 37].
our opinion, the repeated platelet activation induced bySeveral reports have pointed out that HD induces
HD procedures would lead to platelet exhaustion byplatelet activation [41–43], which mainly depends on the
compromising signal-transduction mechanisms. More-geometry of the dialyzer and the biocompatibility of the
over, our results suggest that derangement of the cytoskel-dialysis membrane used [44]. Until now, HD-induced
etal organization or a lack of synchronization between theplatelet activation has been indirectly estimated by mea-
cytoskeletal assembly and the signal transduction pro-suring increases in plasma levels of different intraplatelet
cesses may lead to impaired platelet function.substances or by the detection of P-selectin (GMP-140)
expression on platelet membrane by flow cytometry [45].
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